Centre National De La Recherche Scientifique

Universitè De Montpellier

Institut Curie

Abivax

Cécile Apolit

Jamal Tazi

Romain Najman

Didier Scherrer

Florence Mahuteau

Julien Santo

Florence Mahuteau-betzer

Florence Mahuteau-Betzer

Frederic Labeguere

Brice Sautier

Natacha Bienvenu

Elisa Azzali

A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein Rrepresents a chlorine atom or a hydrogen atom, R represents a (C-C)alkyl group, a (C-C)cycloalkyl group, a halogen atom, a (C-C)alkoxy group, a —SO—NRRgroup, a —SOH group, a —OH group, a —O—SO—ORgroup or a —O—P(═O)—(OR)(OR) group, Rrepresents (i) a CFgroup, (ii) a (C-C)alkyl group, (iii) a (C-C)cycloalkyl or a (C-C)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and Rrepresents a hydrogen atom, a (C-C)alkyl group, a (C-C)cycloalkyl or a (C-C)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Phenyl-n-quinoline derivatives for treating a RNA virus infection

A compound of formula (Ie): wherein Yrepresents an aryl group, Xrepresents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH)NH— group, a —C(OH)(CHOH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO— group, or a —SO—NH— group, Yrepresents a hydrogen atom, a hydroxyl group, a (C-C)alkoxy group, a —CHC(OH), a COOR, wherein Rrepresents a hydrogen atom or a (C-C)alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(OR)(OR') group, wherein Rand R′independently represents a hydrogen atom or a (C-C)alkyl group, an oxetanyl group, a —Si(CH)group, a —NHCOO—(C-C)alkyl group, or a —CRRRgroup, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Aryl-n-aryl derivatives for treating a RNA virus infection

A compound of formula (Ic) a group, a group, a morpholinyl group, optionally substituted by a (C-C)alkyl group, a piperazinyl group, a piperidinyl group, or a —CRRRgroup, or any of its pharmaceutically acceptable salt.

A compound: wherein Xrepresents an alkenylene group, a &#x2014;NH&#x2014;CO&#x2014; group, a &#x2014;CO&#x2014;NH&#x2014; group, Yrepresents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, Xrepresents &#x2014;O&#x2014;, &#x2014;CO&#x2014;NH&#x2014;, &#x2014;NH&#x2014;CO&#x2014;NH&#x2014;, &#x2014;OCH&#x2014;, &#x2014;NH&#x2014;CO&#x2014;, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or &#x2014;SO&#x2014;NH&#x2014;, and Yrepresents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C-C)alkyl group, a piperazinyl group, optionally substituted by a (C-C)alkyl group, or &#x2014;CRRRor alternatively X&#x2014;Yrepresents &#x2014;CONRR, wherein Rand Rform, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C-C)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

Growing community of inventors

Grabels, France

Cécile Apolit